Sign inCreate account

Report workspace tools

NCT04093336UNKNOWNanonymous

Effect of Human Umbilical Cord Mesenchymal Stem Cells(MSCs) Transplantation for on Prognosis of Acute Cerebral Infarction Patients

Sponsor

Source record

Shanghai East Hospital

Phase

Source record

PHASE1

Modality

AI-normalized

cell therapy

Target

AI-normalized

human umbilical cord mesenchymal stem cells, Placebo, standardized treatment

Indication / condition

AI-normalized

Infarction, Middle Cerebral Artery

Intervention

Source record

human umbilical cord mesenchymal stem cells, Placebo, standardized treatment

Source & freshness

Source record

NCT ID

NCT04093336

Original source

ClinicalTrials.gov

Source last updated

Apr 18, 2023

Ingested at

Jun 08, 2026

Internal sync

Jun 08, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04093336

Title

Effect of Human Umbilical Cord Mesenchymal Stem Cells(MSCs) Transplantation for on Prognosis of Acute Cerebral Infarction Patients

Sponsor

Shanghai East Hospital

Status

UNKNOWN

Phase

PHASE1

Condition raw

Infarction, Middle Cerebral Artery, Infarction, Anterior Cerebral Artery, Cerebral Infarction, Stroke, Ischemic, Acute Stroke, Brain Infarction, Infarction, PCA, Infarction, Posterior Circulation, Brain

Condition normalized

Infarction, Middle Cerebral Artery, Infarction, Anterior Cerebral Artery, Cerebral Infarction, Stroke, Ischemic, Acute Stroke, Brain Infarction, Infarction, PCA, Infarction, Posterior Circulation, Brain

Modality raw

cell therapy

Modality normalized

cell therapy

Target raw

human umbilical cord mesenchymal stem cells, Placebo, standardized treatment

Target normalized

human umbilical cord mesenchymal stem cells, Placebo, standardized treatment

Interventions

human umbilical cord mesenchymal stem cells, Placebo, standardized treatment

Public preview

Source record

This is a placebo controlled, randomized, double blinded study including Phase 1 and Phase 2. Phase I study is a safety assessment and Phase 2 study is incline to assess effectiveness of MSCs. Potential subjects must be screened and consented before enrolled.

The primary objective of this study is to determine the effects of early intravenous infusion of allogeneic human umbilical cord mesenchymal stem cells (HucMSCs or MSCs used in the following section) for patients with acute ischemic stroke. Eligible patients will receive a single dose of MSCs or placebo within 24 hours after stroke. Patients will be followed for 2 years post infusion for safety and efficacy (change in neurological symptoms and quality of life). Assessments will occur during transplantation and at 3,7, 14 days and1,3, 6, 12, 18 and 24 months after infusions of stem cells.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Effect of Human Umbilical Cord Mesenchymal Stem Cells(MSCs) Transplantation for on Prognosis of Acute Cerebral Infarction Patients

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04093336

Status

UNKNOWN

Phase

PHASE1

Sponsor

Shanghai East Hospital

Executive brief

Investment-Ready Snapshot

This is a placebo controlled, randomized, double blinded study including Phase 1 and Phase 2. Phase I study is a safety assessment and Phase 2 study is incline to assess effectiveness of MSCs. Potential subjects must be screened and consented before enrolled. The primary objective of this study is to determine the effects of early intravenous infusion of allogeneic human umbilical cord mesenchymal stem cells (HucMSCs or MSCs used in the following section) for patients with acute ischemic stroke. Eligible patients will receive a single dose of MSCs or placebo within 24 hours after stroke. Patients will be followed for 2 years post infusion for safety and efficacy (change in neurological symptoms and quality of life). Assessments will occur during transplantation and at 3,7, 14 days and1,3, 6, 12, 18 and 24 months after infusions of stem cells.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 18, 2023
Internal syncJun 08, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04093336

Indication

Infarction, Middle Cerebral Artery

Modality

cell therapy

Target

human umbilical cord mesenchymal stem cells, Placebo, standardized treatment

Intervention

human umbilical cord mesenchymal stem cells, Placebo, standardized treatment

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.